Skip to main content

Table 4 The number of attacks and the treatment characteristics in the three groups of patients

From: Value co-creation in healthcare: evidence from innovative therapeutic alternatives for hereditary angioedema

  Number of attacks Number of treated attacks (compliant and non-compliant) % of treated attacks Number of vials Average number of vials per attack
Strategy 1 (home-based)
Icatibant 188 84 44.68% 93 1.11
PdC1-INH 556 435 78.24% 810 1.86
Strategy 2 (hospital-based)
Hospital-based PdC1-INH 54 26 48.15% 67 2.58
Total Strategy 1 744 519 69.76% 903 1.74
Total Strategy 2 54 26 48.15% 67 2.58
  1. pdC1-INH plasma-derived C1-esterase inhibitor concentrate